Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
We conducted a phase 3, randomized, open-label study involving patients infected with HCV genotype 1 who had not had a sustained virologic response after treatment with peginterferon and ribavirin, with or without a protease inhibitor.
Ledipasvir and Sofosbuvir.pdf
Documento Adobe Acrobat 361.6 KB

Immunomodulatory role of the hepatocyte during HCV infection
PMC3757554 : Hepatitis C virus (HCV) is remarkable at disrupting human immunity to establish chronic infection. Accumulation of regulatory T cells (Tregs) and up-regulation of inhibitory signaling pathways (such as Tim-3/Gal-9) play pivotal roles in suppressing antiviral effector T cells (Teffs) that are essential for viral clearance.
Immunomodulatory role of the hepatocyte
Documento Adobe Acrobat 1.5 MB
Approaches to hepatitis C treatment and cure using NS5A inhibitors
PMC3949698 : Recent progress in the understanding of hepatitis C virus (HCV) biology and the availability of in vitro models to study its replication have facilitated the development of direct-acting antiviral agents (DAAs) that target specific steps in the viral replication cycle.
Approaches to hepatitis C treatment.pdf
Documento Adobe Acrobat 2.4 MB
Chronic hepatitis C: future treatment
PMC3891518 : The launch of first-generation protease inhibitors (PIs) is a major step forward in HCV treatment. However, the major advance is up to now restricted to genotype 1 (GT-1) patients.
Chronic hepatitis C_future treatment.pdf
Documento Adobe Acrobat 331.4 KB
Chronic hepatitis C virus infection in children
PMC3915892 : Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy.
The experiences with therapy in children with chronic hepatitis C are based on earlier and continuing data from adult trials.
Chronic hepatitis C virus infection in c
Documento Adobe Acrobat 219.1 KB
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
DOI: 10.1056/NEJMoa1316145
In clinical trials, treatment with a combination of the nucleotide polymerase inhibitor sofosbuvir and the antiviral drug ribavirin was associated with high response rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower response rates among patients with HCV genotype 3 infection.
Sofosbuvir and Ribavirin hcv.pdf
Documento Adobe Acrobat 460.2 KB